Polymer-Free Biolimus A9-Coated stents in the treatment of de novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinicaloutcomes of the prospective, multicenter biofreedom fim clinical trial
JACC cardiovasc. interv
; 9(1): 51-64, 2016.
Article
em En
| SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1064068
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
OBJECTIVES:
The purpose of this study was to evaluate the efficacy and long-term outcomes of a novel polymer/carrier-free drug-coated stent (DCS) in patients with de novo coronary lesions.BACKGROUND:
The BioFreedom (BFD) DCS incorporates a low-profile, stainless-steel platform, with a surface that has been modified to create a selectively microstructured abluminal surface that allows adhesion and further release of Biolimus A9 (Biosensors Europe SA, Morges, Switzerland).METHODS:
A total of 182 patients (183 lesions) were randomized into a 111 ratio for treatment with BFD "standard dose" (BFD) or BFD "low dose" (BFD-LD) versus first-generation paclitaxel-eluting stents (PES) at 4 sites in Germany.RESULTS:
Baseline and procedural characteristics were well matched. At 4-month angiographic follow-up (Cohort 1, n = 75), in-stent late lumen loss (LLL) was significantly lower with BFD and BFD-LD versus PES (0.08 and 0.12 mm vs. 0.37 mm, respectively; p < 0.0001 for BFD vs. PES, and p = 0.002 for BFD-LD vs. PES). At 12 months (Cohort 2, n = 107), in-stent LLL (primary endpoint) was 0.17 mm in BFD versus 0.35 mm in PES (p = 0.001 for noninferiority; p = 0.11 for superiority)...
Buscar no Google
Coleção SES:
Producao_cientifica
Base de dados:
SES-SP
/
SESSP-IDPCPROD
Assunto principal:
Stents
/
Doença das Coronárias
/
Stents Farmacológicos
/
Intervenção Coronária Percutânea
Tipo de estudo:
Clinical_trials
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article